ReviewJournal of surgical oncology2026
Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years.
Review in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pleural Pseudomyxoma Secondary to Appendiceal Mucinous Adenocarcinoma: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A prognostic assessment of mucinous appendiceal adenocarcinoma (MACA) patients with peritoneal metastases in the absence of lymph node metastases needs to be precisely defined. All patients were treated by a complete cytoreductive surgery (CRS) and perioperative chemotherapy. Preoperative clinical features including tumor markers were recorded within 1 week prior to CRS. Data regarding perioperative intraperitoneal chemotherapy, histologic features and reoperative surgery were gathered after CRS. Impact on overall survival of these factors was analyzed by univariant and multivariant analysis. One hundred and ninety-eight patients with mucinous appendiceal adenocarcinoma causing pseudomyxoma peritonei were available for study. They had a median survival of 11 years. Hyperthermic intraperitoneal chemotherapy (HIPEC) with a median survival of 12.0 years was superior to early postoperative intraperitoneal chemotherapy (EPIC) with a median survival of 4.0 years (HR 2.09, p = 0.002). By histopathology, the intermediate type (MACA-Int) was associated with the longest survival and poorly differentiated (MACA-3) the poorest survival. Peritoneal cancer index and tumor marker elevations had no impact on survival. Clinical features and preoperative tumor markers had little or no prognostic value in selection of MACA patients for CRS. Intermediate histologic subtype and use of HIPEC indicated a favorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.